This is a single arm Phase II cohort of RO7198457 in patients with circulating tumor DNA (ctDNA) positive surgically resected Stage IV CRC after standard of care adjuvant therapy. The study will test whether the vaccine can reduce recurrence of the cancer.

A study designed to evaluate the effects of vitamin D and aspirin supplementation, a plant-based diet, and physical activity on CRC patients with minimal residual disease. The study aims to assess whether such lifestyle changes can eradicate ctDNA in the blood and reduce cancer recurrence.

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

This trial studies the side effects and best dose of SX-682 that can be given alone and in combination with nivolumab in treating patients with RAS-Mutated, microsatellite stable (MSS) colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). SX-682 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 alone and together with nivolumab may kill more tumor cells.

A study designed to evaluate the effects of vitamin D and aspirin supplementation, a plant-based diet, and physical activity on CRC patients with minimal residual disease. The study aims to assess whether such lifestyle changes can eradicate ctDNA in the blood and reduce cancer recurrence.

Clinical trial of cord-blood NK cells and cetuximab for minimal residual disease in stages II-IV colorectal cancer.

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal or colon. The study will test whether the vaccine can reduce recurrence of the cancer.

A study in the US cooperative groups for patients with low risk, Stage III colon cancer (T1-3, N1) to evaluate whether immediate adjuvant chemotherapy is needed for patients that are ctDNA negative, and if more intensive adjuvant chemotherapy may be beneficial for patients that are ctDNA positive.

ctDNA positive patients randomized to FOLFIRI (12 cycles) or surveillance. If MSI-H, receive nivolumab (12 cycles). If BRAF mutation is present, receive encorafenib, binimetinib, and cetuximab (12 cycles).